Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancercellchemotherapystageconcurrent
  Phrases that lowered it: clinical trialphase iiinormalpatientsrandomized
• Sponsor's past termination rate: 2.3% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 30% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 32 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: supportive care (raises risk) · Design
• Drug's FAERS reports marked serious: 90% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 10 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 44 (lowers risk) · Sponsor's track record
• Keywords listed: 20 (raises risk) · Design
• Maximum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin NCT04541355 · started 2020 · scored riskier than 97% of active trials completed
• NAC to Prevent Cisplatin-induced Hearing Loss NCT02094625 · started 2016 · scored riskier than 90% of active trials completed
• SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease NCT05628233 · started 2022 · scored riskier than 35% of active trials completed
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors NCT01259479 · started 2010 · scored riskier than 64% of active trials completed
• Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss NCT02997189 · started 2016 · scored riskier than 41% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.